CN106102750A - 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 - Google Patents

治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 Download PDF

Info

Publication number
CN106102750A
CN106102750A CN201380076382.XA CN201380076382A CN106102750A CN 106102750 A CN106102750 A CN 106102750A CN 201380076382 A CN201380076382 A CN 201380076382A CN 106102750 A CN106102750 A CN 106102750A
Authority
CN
China
Prior art keywords
cangrelor
pci
administration
ticagrelor
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380076382.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·A·阿尔库吕斯-米恩韦尔
S·斯凯伊安内克
J·普拉茨
D·J·施耐德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/792,056 external-priority patent/US9427448B2/en
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Priority to CN202210682855.1A priority Critical patent/CN115120606A/zh
Publication of CN106102750A publication Critical patent/CN106102750A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380076382.XA 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法 Pending CN106102750A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210682855.1A CN115120606A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13/792,056 US9427448B2 (en) 2009-11-11 2013-03-09 Methods of treating, reducing the incidence of, and/or preventing ischemic events
US13/792,056 2013-03-09
US201361815735P 2013-04-25 2013-04-25
US61/815,735 2013-04-25
PCT/US2013/043136 WO2014143107A1 (en) 2013-03-09 2013-05-29 Methods of treating, reducing the incidence of, and/or preventing ischemic events

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210682855.1A Division CN115120606A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法

Publications (1)

Publication Number Publication Date
CN106102750A true CN106102750A (zh) 2016-11-09

Family

ID=51537409

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380076382.XA Pending CN106102750A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法
CN202210682855.1A Pending CN115120606A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210682855.1A Pending CN115120606A (zh) 2013-03-09 2013-05-29 治疗局部缺血事件、减少局部缺血事件的发生和/或预防局部缺血事件的方法

Country Status (10)

Country Link
EP (2) EP3978002A1 (https=)
JP (3) JP6247708B2 (https=)
CN (2) CN106102750A (https=)
AU (1) AU2013381855B2 (https=)
BR (1) BR112015022070B1 (https=)
CA (1) CA2904523C (https=)
EA (1) EA034550B1 (https=)
ES (1) ES2904256T3 (https=)
PL (1) PL2964233T3 (https=)
WO (1) WO2014143107A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740736A (zh) * 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112030A1 (en) * 2009-11-11 2011-05-12 The Medicines Company Methods of treating or preventing stent thrombosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100315612B1 (ko) 1993-02-10 2002-06-20 추후제출 N-알킬-2-치환아데노신트리포스페이트동족체
ID21635A (id) 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
SE9904377D0 (sv) 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
WO2009140092A1 (en) * 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) * 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20100297675A1 (en) * 2008-11-24 2010-11-25 Huayun Deng Substrate and method for culturing breast cells
MX2011006995A (es) * 2008-12-30 2011-09-27 Thrombologic Aps Metodos para identificar pacientes criticamente enfermos en riesgo incrementado de desarrollar nsuficiencia organica y compuestos para el tratamiento de la misma.
NZ596747A (en) * 2009-06-16 2014-01-31 Cardoz Ab Crystalline form of pemirolast
EA034550B1 (ru) * 2013-03-09 2020-02-19 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Способы лечения, снижения частоты и/или профилактики ишемических событий

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110112030A1 (en) * 2009-11-11 2011-05-12 The Medicines Company Methods of treating or preventing stent thrombosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NIHAR R. DESAI等: "The State of Periprocedural Antiplatelet Therapy After Recent Trials", 《JACC: CARDIOVASCULAR INTERVENTIONS》 *
PHILIPPE GABRIEL STEG等: "Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis", 《CIRCULATION》 *
ROBERT A. HARRINGTON等: "Platelet Inhibition with Cangrelor in Patients Undergoing PCI", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110740736A (zh) * 2017-06-23 2020-01-31 奇斯药制品公司 预防体-肺动脉分流术血栓形成的方法
US12502400B2 (en) 2017-06-23 2025-12-23 Chiesi Farmaceutici S.P.A. Method of preventing of systemic-to-pulmonary-artery shunt thrombosis

Also Published As

Publication number Publication date
CA2904523A1 (en) 2014-09-18
EA034550B1 (ru) 2020-02-19
WO2014143107A1 (en) 2014-09-18
JP2018002739A (ja) 2018-01-11
JP2019178177A (ja) 2019-10-17
AU2013381855A1 (en) 2015-10-22
JP2016510738A (ja) 2016-04-11
PL2964233T3 (pl) 2022-04-25
EA201591683A1 (ru) 2016-08-31
EP2964233A4 (en) 2016-10-19
CN115120606A (zh) 2022-09-30
EP2964233A1 (en) 2016-01-13
JP6840197B2 (ja) 2021-03-10
CA2904523C (en) 2024-01-09
BR112015022070B1 (pt) 2022-01-18
EP3978002A1 (en) 2022-04-06
BR112015022070A2 (pt) 2017-07-18
AU2013381855B2 (en) 2018-08-02
JP6247708B2 (ja) 2017-12-13
ES2904256T3 (es) 2022-04-04
EP2964233B1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
US11351187B2 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20240350638A1 (en) Methods of treating or preventing stent thrombosis
US20230210880A1 (en) Methods of Treating, Reducing the Incidence of, and/or Preventing Ischemic Events
US8680052B1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
US20250099466A1 (en) Milvexian for prevention and treatment of thromboembolic disorders
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
HK40073112A (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2014142780A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
WO2015054542A1 (en) Methods of treating, reducing the incidence of, and/or preventing ischemic events
KR20260051984A (ko) 급성 관상동맥 증후군을 갖는 환자에서 유해 뇌혈관 사건 또는 유해 심혈관 사건을 치료 또는 예방하기 위한 밀벡시안의 용도
TW202241446A (zh) 治療方法
TW200409638A (en) Use of MELOXICAM in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20161109